MA55967A - Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple - Google Patents

Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple

Info

Publication number
MA55967A
MA55967A MA055967A MA55967A MA55967A MA 55967 A MA55967 A MA 55967A MA 055967 A MA055967 A MA 055967A MA 55967 A MA55967 A MA 55967A MA 55967 A MA55967 A MA 55967A
Authority
MA
Morocco
Prior art keywords
methods
multiple myeloma
treating multiple
antibody administration
antibody
Prior art date
Application number
MA055967A
Other languages
English (en)
Inventor
Heloise Audat
Zambrano Frank Campana
Sylvia Marion
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA55967A publication Critical patent/MA55967A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055967A 2019-05-14 2020-05-13 Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple MA55967A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US201962899088P 2019-09-11 2019-09-11
EP20305223 2020-03-03

Publications (1)

Publication Number Publication Date
MA55967A true MA55967A (fr) 2022-03-23

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055967A MA55967A (fr) 2019-05-14 2020-05-13 Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple

Country Status (15)

Country Link
US (1) US20210171650A1 (fr)
EP (1) EP3969004A1 (fr)
JP (2) JP7801132B2 (fr)
KR (1) KR20220008305A (fr)
CN (2) CN120501855A (fr)
AU (1) AU2020274169A1 (fr)
BR (1) BR112021022503A2 (fr)
CA (1) CA3140034A1 (fr)
CO (1) CO2021016606A2 (fr)
IL (1) IL287832A (fr)
MA (1) MA55967A (fr)
MX (1) MX2021013910A (fr)
SG (1) SG11202112513YA (fr)
TW (1) TW202108624A (fr)
WO (1) WO2020232173A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020250033A1 (fr) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Polythérapies utilisant des anticorps cd-38
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3313441B1 (fr) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP7801132B2 (ja) 2026-01-16
WO2020232173A1 (fr) 2020-11-19
US20210171650A1 (en) 2021-06-10
TW202108624A (zh) 2021-03-01
EP3969004A1 (fr) 2022-03-23
CN120501855A (zh) 2025-08-19
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (fr) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
SG11202112513YA (en) 2021-12-30
JP2022532356A (ja) 2022-07-14
IL287832A (en) 2022-01-01
CN114080233A (zh) 2022-02-22
BR112021022503A2 (pt) 2021-12-28
MX2021013910A (es) 2022-03-11
KR20220008305A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
EP4046438A4 (fr) Procédés et appareils pour l'amélioration de l'agrégation de porteuses sl
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3941924A4 (fr) Technologies utiles pour la préparation d'oligonucléotides
EP3765094A4 (fr) Compositions de régulation génique et procédés pour améliorer l'immunothérapie
EP3927749A4 (fr) Anticorps anti-cd33 et leurs procédés d'utilisation pour traiter le cancer
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP4081518A4 (fr) Associations d'agents de dégradation du récepteur d'?strogènes et d'inhibiteurs de kinase dépendante de cyclines pour le traitement du cancer
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
EP4025256A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3846846A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
EP3799602A4 (fr) Composés et procédés pour réduire l'expression d'atxn3
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3687537A4 (fr) Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
EP3908292A4 (fr) Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules